EUVIMEDEUVIMED entdecken
VergleichsstudieÄquivalenzstudie

Rivaroxaban versus enoxaparin as thromboprophylaxis in degenerative spine surgery: a randomized blinded non-inferiority study

Hamid Reza Khayat Kashani iD, Sohrab Salimi iD, Pooyan Alizadeh iD, Poorya Paryan, Zahra Mohammadi iD, Naser Kachoueian iD, Maryam Heli iD, Nasibeh Ghalandari, Hadi Esmaily iD

European Spine Journal · 2025

DOI: 10.1007/s00586-025-08747-7 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Spine Journal, 2025. Verfasst von Hamid Reza Khayat Kashani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Imam Hossein medical centre, Shahid Beheshti University of Medical Sciences, Madani street, Tehran, Iran. Hauptthemen laut MEDLINE: Enoxaparin, Intervertebral Disc Degeneration, Postoperative Complications, Rivaroxaban. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: School of Medicine, Shahid Beheshti University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Venous thromboembolism (VTE) is a significant postoperative complication. The most recommended prophylactic measures involve using the unfractionated heparin, and low molecular weight heparins. Since oral anticoagulants can be administered orally and are cost-effective, they have recently gained attention as a newer intervention. This study aimed to compare the effects of rivaroxaban, and enoxaparin thromboprophylaxis in degenerative spine surgeries. METHOD: Patients diagnosed with degenerative disc disease, and undergoing spinal surgery were randomly assigned to receive either a subcutaneous injection of 40 mg enoxaparin or 10 mg oral rivaroxaban daily in a non-inferiority trial. The evaluation at two weeks, and three months after surgery included the assessments of VTE and other postoperative complications. RESULT: According to the study protocol, 220 patients were enrolled in the study and included in the intention-to-treat analysis. However, the results were only available for 204 subjects as per-protocol. Ninety-seven in enoxaparin and 107 in rivaroxaban group. VTE was detected in 4 patients (3.6%) in the enoxaparin group, and 2 patients (1.9%) in the rivaroxaban group (P = 0.154). Reoperation rates were significantly higher in the enoxaparin group (P = 0.008). Moreover, the enoxaparin group experienced a significantly longer hospital stay (P = 0.033). However, other outcomes did not show significant differences between two groups (P > 0.05). CONCLUSION: This study shows that rivaroxaban effectively prevents VTE incidence in degenerative disc spinal surgeries which is non-inferior to enoxaparin in terms of VTE prophylaxis. Furthermore, the patients in the rivaroxaban group experienced shorter hospital stays and a lower necessity for reoperation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EnoxaparinIntervertebral Disc DegenerationPostoperative ComplicationsRivaroxabanVenous ThromboembolismAdultAgedFemaleHumansMaleMiddle AgedAnticoagulantsFactor Xa Inhibitors

Stichwörter der Autor:innen

Degenerative disc diseaseEnoxaparinRivaroxabanSpinal surgeryVenous thromboembolic event

Substanzen

AnticoagulantsEnoxaparinFactor Xa InhibitorsRivaroxaban

Autor:innen und Institutionen

  • Department of Neurosurgery, Imam Hossein medical centre, Shahid Beheshti University of Medical Sciences, Madani street, Tehran, Iran.
  • Department of Anaesthesiology, Imam Hossein medical centre, Shahid Beheshti University of Medical Sciences, Madani street, Tehran, Iran.
  • Department of Neurosurgery, Jundishapur University of Medical Sciences, Ahwaz, Iran.
  • Department of Surgery, Imam Hossein medical centre, Shahid Beheshti University of Medical Sciences, Madani street, Tehran, Iran.
  • Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Esmaily_hadi@sbmu.ac.ir.

ORCID-Profile: Hamid Reza Khayat Kashani, Sohrab Salimi, Pooyan Alizadeh, Zahra Mohammadi, Naser Kachoueian, Maryam Heli, Hadi Esmaily

Förderung

  • School of Medicine, Shahid Beheshti University of Medical Sciences

Zitieren

APA

Kashani, H. R. K., Salimi, S., Alizadeh, P., Paryan, P., Mohammadi, Z., Kachoueian, N., Heli, M., Ghalandari, N., & Esmaily, H. (2025). Rivaroxaban versus enoxaparin as thromboprophylaxis in degenerative spine surgery: a randomized blinded non-inferiority study. European Spine Journal. https://doi.org/10.1007/s00586-025-08747-7

Vancouver

Kashani HRK, Salimi S, Alizadeh P, Paryan P, Mohammadi Z, Kachoueian N, et al. Rivaroxaban versus enoxaparin as thromboprophylaxis in degenerative spine surgery: a randomized blinded non-inferiority study. European Spine Journal. 2025. doi:10.1007/s00586-025-08747-7

BibTeX
@article{Kashani2025,
  author = {Kashani, Hamid Reza Khayat and Salimi, Sohrab and Alizadeh, Pooyan and Paryan, Poorya and Mohammadi, Zahra and Kachoueian, Naser and Heli, Maryam and Ghalandari, Nasibeh and Esmaily, Hadi},
  title = {Rivaroxaban versus enoxaparin as thromboprophylaxis in degenerative spine surgery: a randomized blinded non-inferiority study},
  journal = {European Spine Journal},
  year = {2025},
  doi = {10.1007/s00586-025-08747-7}
}
Kostenlos starten →